New hope for tough blood cancers? early trial tests regorafenib
NCT ID NCT03042689
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This early-phase study tested the drug regorafenib in 16 adults with advanced blood cancers like acute myeloid leukemia that had stopped responding to other treatments. The main goal was to find the safest dose and see how the drug affects cancer-related cell signals. While not a cure, the study aimed to control the disease and gather important safety information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts general Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.